Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06225596
Title	Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Recruitment	Recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	BicycleTx Limited
Indications	transitional cell carcinoma urethra transitional cell carcinoma ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma
Therapies	Avelumab + Carboplatin + Gemcitabine Avelumab + Cisplatin + Gemcitabine BT8009 BT8009 + Pembrolizumab
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| POL \| ITA \| ISR \| HUN \| GBR \| FRA \| ESP \| DEU \| CAN \| BEL \| AUS \| ARG